GlassScriptPhysician profile
Todd W Campbell
NPI 1720059553
$742.22
in general payments reported to CMS, 2019-2025
18 companies · $65.02 in 2025
The $65.02 reported for 2025 was less than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $48.24 · 2021: $78.98 · 2022: $261 · 2023: $50.49 · 2024: $124 · 2025: $65.02.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $239.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $123.98 | 2024 | |
| Organogenesis INC. | $123.49 | 2022 | |
| Medtronic USA, INC. | $90.90 | 2019-2020 | |
| Genzyme Corporation | $75.92 | 2022-2023 | |
| Glaxosmithkline, LLC. | $64.54 | 2021-2023 | Nucala |
| Alk-Abello, INC | $39.30 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $32.96 | 2020-2022 | |
| Lilly USA, LLC | $23.45 | 2025 | Zepbound |
| Inspire Medical Systems, INC. | $21.95 | 2025 | Inspire |
| Kaleo, INC. | $21.51 | 2022 | |
| Sumitomo Pharma America, INC. | $19.62 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $16.94 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.79 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.48 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.34 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $14.99 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.06 | 2019 | |
| Glenmark Therapeutics INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.